Replimune Group, Inc. (REPL)
- Previous Close
6.42 - Open
6.41 - Bid 6.31 x 100
- Ask 6.34 x 300
- Day's Range
6.20 - 6.66 - 52 Week Range
5.89 - 24.81 - Volume
631,809 - Avg. Volume
1,276,938 - Market Cap (intraday)
388.585M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-3.16 - Earnings Date May 16, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.56
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
www.replimune.comRecent News: REPL
Performance Overview: REPL
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REPL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REPL
Valuation Measures
Market Cap
388.58M
Enterprise Value
-1.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.92
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.41%
Return on Equity (ttm)
-41.29%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-209.96M
Diluted EPS (ttm)
-3.16
Balance Sheet and Cash Flow
Total Cash (mrq)
466.35M
Total Debt/Equity (mrq)
17.98%
Levered Free Cash Flow (ttm)
-107.54M